Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

27.00
+0.30111.13%
Post-market: 27.000.00000.00%16:10 EDT
Volume:392
Turnover:10.60K
Market Cap:5.40M
PE:- -
High:27.00
Open:27.00
Low:27.00
Close:26.70
52wk High:27.94
52wk Low:22.63
Shares:200.00K
Float Shares:200.00K
Volume Ratio:0.61
T/O Rate:0.20%
Dividend:0.41
Dividend Rate:1.53%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Ataibeckley - Hart-Scott-Rodino Waiting Period for Merger with Eli Lilly Expired on Aug 28, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 01

Hims & Hers Health Enters Australia, Marks First Asia-Pacific Market Presence

Reuters
·
Sep 01

Hims & Hers Enters Australia in First Asia-Pacific Expansion

Reuters
·
Sep 01

Hims & Hers Offers GLP-1 Weight-Loss Drugs, Men's Health Treatments in Australia

Reuters
·
Sep 01

Sector Update: Healthcare Stocks Decline Monday Afternoon

MT Newswires Live
·
Sep 01

Moderately bullish activity in Eli Lilly with shares down 1.26%

TIPRANKS
·
Sep 01

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Dow Jones
·
Sep 01

Top Midday Stories: Stocks Fall, Oil Rises Amid Renewed Fighting in Middle East; Utility Shares Fall After California Wildfire Legislation

MT Newswires Live
·
Aug 31

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
Aug 31

Novo Nordisk Advances DKK 15 Billion Share Buyback Programme Through Late August 2026

TIPRANKS
·
Aug 31

Eli Lilly Expands Beyond Weight-Loss Dominance With Potential $2.88B Autoimmune Deal

Stock News
·
Aug 31

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31